These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 20665209)

  • 1. Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies.
    Stoops WW; Hatton KW; Lofwall MR; Nuzzo PA; Walsh SL
    Psychopharmacology (Berl); 2010 Oct; 212(2):193-203. PubMed ID: 20665209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers.
    Walsh SL; Nuzzo PA; Lofwall MR; Holtman JR
    Drug Alcohol Depend; 2008 Dec; 98(3):191-202. PubMed ID: 18606504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Within-subject comparison of the psychopharmacological profiles of oral hydrocodone and oxycodone combination products in non-drug-abusing volunteers.
    Zacny JP; Gutierrez S
    Drug Alcohol Depend; 2009 Apr; 101(1-2):107-14. PubMed ID: 19118954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Likeability and abuse liability of commonly prescribed opioids.
    Wightman R; Perrone J; Portelli I; Nelson L
    J Med Toxicol; 2012 Dec; 8(4):335-40. PubMed ID: 22992943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Within-subject comparison of the psychopharmacological profiles of oral oxycodone and oral morphine in non-drug-abusing volunteers.
    Zacny JP; Lichtor SA
    Psychopharmacology (Berl); 2008 Jan; 196(1):105-16. PubMed ID: 17899018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abuse liability assessment of hydrocodone under current draft regulatory guidelines.
    Gauvin DV; McComb M; Code R; Dalton JA; Baird TJ
    J Pharmacol Toxicol Methods; 2015; 75():118-29. PubMed ID: 25969422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subjective, psychomotor, and physiological effects profile of hydrocodone/acetaminophen and oxycodone/acetaminophen combination products.
    Zacny JP; Gutierrez S
    Pain Med; 2008; 9(4):433-43. PubMed ID: 18489634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative potency of intravenous oxymorphone compared to other µ opioid agonists in humans - pilot study outcomes.
    Babalonis S; Comer SD; Jones JD; Nuzzo P; Lofwall MR; Manubay J; Hatton KW; Whittington RA; Walsh SL
    Psychopharmacology (Berl); 2021 Sep; 238(9):2503-2514. PubMed ID: 34106317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers.
    Zacny JP; Gutierrez S
    Psychopharmacology (Berl); 2003 Nov; 170(3):242-254. PubMed ID: 12955305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profiling the subjective, psychomotor, and physiological effects of a hydrocodone/acetaminophen product in recreational drug users.
    Zacny JP; Gutierrez S; Bolbolan SA
    Drug Alcohol Depend; 2005 Jun; 78(3):243-52. PubMed ID: 15893155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human Abuse Potential of Oral NKTR-181 in Recreational Opioid Users: A Randomized, Double-Blind, Crossover Study.
    Ge X; Henningfield JE; Siddhanti S; Jobes J; Lu L; Xie S; Ziola M; Kelsh D; Vince B; Di Fonzo CJ; Tagliaferri M; Zalevsky J; Doberstein SK; Hoch U; Eldon MA
    Pain Med; 2020 Feb; 21(2):e114-e126. PubMed ID: 31553457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abuse potential of intravenous oxycodone/naloxone solution in nondependent recreational drug users.
    Colucci SV; Perrino PJ; Shram M; Bartlett C; Wang Y; Harris SC
    Clin Drug Investig; 2014 Jun; 34(6):421-9. PubMed ID: 24756361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of oxycodone, hydrocodone, and morphine on the responses of D2/D3 dopamine receptors.
    Emery MA; Bates ML; Wellman PJ; Eitan S
    Behav Brain Res; 2015 May; 284():37-41. PubMed ID: 25617530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers.
    Walsh SL; Heilig M; Nuzzo PA; Henderson P; Lofwall MR
    Addict Biol; 2013 Mar; 18(2):332-43. PubMed ID: 22260216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosing protocol and analgesic efficacy determine opioid tolerance in the mouse.
    Madia PA; Dighe SV; Sirohi S; Walker EA; Yoburn BC
    Psychopharmacology (Berl); 2009 Dec; 207(3):413-22. PubMed ID: 19816677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users.
    Smith MD; Webster LR; Lawler J; Lindhardt K; Dayno JM
    Pain Med; 2017 May; 18(5):898-907. PubMed ID: 27633773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human Abuse Potential of the New Opioid Analgesic Molecule NKTR-181 Compared with Oxycodone.
    Webster L; Henningfield J; Buchhalter AR; Siddhanti S; Lu L; Odinecs A; Di Fonzo CJ; Eldon MA
    Pain Med; 2018 Feb; 19(2):307-318. PubMed ID: 28340145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic effects of oral oxymorphone: abuse liability, analgesic profile and direct physiologic effects in humans.
    Babalonis S; Lofwall MR; Nuzzo PA; Walsh SL
    Addict Biol; 2016 Jan; 21(1):146-58. PubMed ID: 25130052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analgesic efficacy and tolerability of intravenous morphine versus combined intravenous morphine and oxycodone in a 2-center, randomized, double-blind, pilot trial of patients with moderate to severe pain after total hip replacement.
    Joppich R; Richards P; Kelen R; Stern W; Zarghooni K; Otto C; Böhmer A; Petzke F; Treptau T; Lefering R; Bäthis H; Neugebauer E
    Clin Ther; 2012 Aug; 34(8):1751-60. PubMed ID: 22795613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004.
    Cicero TJ; Inciardi JA; Muñoz A
    J Pain; 2005 Oct; 6(10):662-72. PubMed ID: 16202959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.